Pilot Phase II Trial for the Evaluation of the Effect of Systemic Low-dose IL-2 on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant, in Patients With High Risk Melanoma (MEL36)

NCT00928902 Phase 2 COMPLETED

This clinical pilot study will test the hypothesis that systemic low-dose IL-2 therapy significantly enhances the immunologic efficacy of a vaccine comprising melanoma peptides plus GM-CSF-in-adjuvant.

Details

Lead sponsor	University of Virginia
Phase	Phase 2
Status	COMPLETED
Enrolment	41
Start date	1999-11
Completion	2005-03

Conditions

• Melanoma

Interventions

• low-dose IL-2
• melanoma vaccine

Primary outcomes

• To evaluate the effect of systemic low-dose IL-2 on the immunogenicity of a vaccine comprising synthetic melanoma peptides plus GM-CSF-in-adjuvant.